<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924820</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0122</org_study_id>
    <secondary_id>NCI-2009-01610</secondary_id>
    <nct_id>NCT00924820</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Bevacizumab for Neoplastic Meningitis</brief_title>
  <official_title>A Pilot Study of Systemically Administered Bevacizumab in Patients With Neoplastic Meningitis (NM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if and how Avastin (bevacizumab) may&#xD;
      affect cancer that has spread to the meninges of the brain or the spinal cord. The safety of&#xD;
      this drug will also be studied.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      1. Primary:&#xD;
&#xD;
      1. Determine preliminary response data of intravenous bevacizumab in patients with NM&#xD;
&#xD;
      a. As measured by clearance of malignant cells from the Cerebrospinal fluid (CSF) at 2, 4, 6,&#xD;
      12, 18, and 24 weeks, then every 8 weeks up to 54 weeks, and&#xD;
&#xD;
      b. Time to neurological progression (TTNP)&#xD;
&#xD;
      2. Secondary:&#xD;
&#xD;
        1. Evaluate the safety of intravenous bevacizumab in patients with NM&#xD;
&#xD;
        2. Further describe the efficacy of this intervention as measured by&#xD;
&#xD;
             1. improvement of MR imaging evidence of disease&#xD;
&#xD;
             2. overall survival&#xD;
&#xD;
             3. maintenance of quality of life&#xD;
&#xD;
        3. Determine effects of systemically administered bevacizumab on CSF, serum, and urine&#xD;
           Vascular endothelial growth factor (VEGF)levels levels&#xD;
&#xD;
        4. Correlate changes in CSF VEGF with response measurements.&#xD;
&#xD;
        5. Correlate primary tumor tissue VEGF expression with CSF VEGF levels&#xD;
&#xD;
        6. Correlate urine VEGF levels with serum and CSF VEGF levels&#xD;
&#xD;
        7. Evaluate serum and CSF VEGF index&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the&#xD;
      growth of blood vessels.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, every 2 weeks, you will receive&#xD;
      bevacizumab by vein over about 1 hour.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At Weeks 2 and 4:&#xD;
&#xD;
        -  Samples of CSF from your spinal cord will be collected to check for the presence of&#xD;
           cancer cells.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests and to check your blood's&#xD;
           ability to clot normally.&#xD;
&#xD;
        -  If you already have an Ommaya reservoir tap in place, samples of CSF from your brain&#xD;
           will be collected to look for the presence of cancer cells.&#xD;
&#xD;
        -  You will be asked about any drugs you may be taking and if you have experienced any side&#xD;
           effects.&#xD;
&#xD;
        -  You will have a neurological exam.&#xD;
&#xD;
      At Weeks 6, 12, 18, and 24, and then every 8 weeks:&#xD;
&#xD;
        -  Samples of CSF from your spinal cord will be collected to check for the presence of&#xD;
           cancer cells.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests and to check your blood's&#xD;
           ability to clot normally.&#xD;
&#xD;
        -  If you already have an Ommaya reservoir tap in place, samples of CSF from your brain&#xD;
           will be collected to look for the presence of cancer cells.&#xD;
&#xD;
        -  You will have a physical exam (Weeks .&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will be asked about any drugs you may be taking and if you have experienced any side&#xD;
           effects.&#xD;
&#xD;
        -  You will have a neurological exam.&#xD;
&#xD;
        -  You will complete the questionnaire about your quality of life.&#xD;
&#xD;
        -  You will have an MRI scan to check the status of the disease.&#xD;
&#xD;
        -  Urine will be collected to test kidney function and for routine tests. If indicated&#xD;
           urine will be collected over a 24 hour period.&#xD;
&#xD;
      Every 2 weeks, your blood pressure will be measured.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will be on study for up to 54 weeks (about 1 year). You will be taken off study early if&#xD;
      the disease gets worse or you experience intolerable side effects.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      If you go off study early, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will have a neurological exam.&#xD;
&#xD;
        -  Samples of CSF from your spinal cord will be collected to look for the presence of&#xD;
           cancer cells.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests and to check your blood's&#xD;
           ability to clot normally. You will complete the questionnaire about your quality of&#xD;
           life.&#xD;
&#xD;
        -  If you already have an Ommaya reservoir tap in place, samples of CSF from your brain&#xD;
           will be collected to look for the presence of cancer cells.&#xD;
&#xD;
      Follow-up Visits:&#xD;
&#xD;
      If you do not go off study early, within 4 weeks after the last dose of study drug, every 4&#xD;
      weeks for 3 months, and then every 3 months from then on, you will have follow-up visits. The&#xD;
      following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  You will have a neurological exam.&#xD;
&#xD;
        -  Samples of CSF from your spinal will be collected to look for the presence of cancer&#xD;
           cells.&#xD;
&#xD;
        -  Blood (about 3 tablespoons) will be drawn for routine tests and to check your blood's&#xD;
           ability to clot normally.&#xD;
&#xD;
      You will have an MRI scan to check the status of the disease.&#xD;
&#xD;
      -If you already have an Ommaya reservoir tap in place, samples of CSF from your brain will be&#xD;
      collected to look for the presence of cancer cells.&#xD;
&#xD;
      This is an investigational study. Bevacizumab is FDA approved and commercially available for&#xD;
      the treatment of colon, breast, and lung cancer. Its use for the treatment of cancer that has&#xD;
      spread to the meninges of the brain or the spinal cord is investigational.&#xD;
&#xD;
      Up to 25 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells</measure>
    <time_frame>1 year (54 weeks) of treatment</time_frame>
    <description>CSF response for participants with Neoplastic Meningitis (NM) or leptomeningeal disease (LMD) defined as conversion from positive to negative cytology or cytometry as measured routinely by total clearance of malignant cells from the CSF where assessments performed from 2 weeks up to week 54 of treatment. Clearance of malignant cells determined by standard clinical testing using cytospin analysis in clinical laboratory. Percentage reflects number of participants of total treated with no response, e.g. participants with continued positive CSF cytology or flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time to Progression (TTP) and Median Time to Neurological Progression (TTNP)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time to Progression defined as time to disease progression measured from date of enrollment, confirmation of disease progression via laboratory testing; Time to neurological progression (TTNP) reflects worsening clinical signs/symptoms or development of new clinical signs/symptoms which investigator feels can be attributed to leptomeningeal disease progression and are severe enough to warrant a change in therapy.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Participant Response: Cerebrospinal Fluid (CSF) Examination</measure>
    <time_frame>1 year (54 weeks) of treatment</time_frame>
    <description>Neoplastic meningitis is considered an unmeasurable metastatic site by Response Evaluation Criteria in Solid Tumors (RECIST), and as such no standardized methodologies are routinely used; therefore response assessed from cerebrospinal fluid (CSF) obtained via lumbar puncture (and from ventricular reservoir if present) and analyzed for malignant cells along with reference recording of magnetic resonance imaging (MRI) of areas of enhancement over time; however, MRI alone in LMD/NM is considered non-evaluable by RECIST criteria. Those participants with only MRI criteria for enrollment, but who later develop CSF positivity after enrollment were declared &quot;progressors&quot; based on the CSF criteria.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neoplastic Meningitis</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of breast cancer, lung cancer or melanoma&#xD;
&#xD;
          2. Diagnosis of NM as proven either by: 1. positive CSF cytology, or 2. magnetic&#xD;
             resonance neuro-imaging, or 3. both&#xD;
&#xD;
          3. Age &gt;/=18 years.&#xD;
&#xD;
          4. Routine laboratory studies adequate with bilirubin &lt;/= 1.5 x upper limit of normal&#xD;
             (ULN), AST &lt; 2.5 x ULN, creatinine &lt;1.0 x ULN, granulocytes &gt;1500, platelets&gt; 75,000;&#xD;
             Hb &gt;/= 9.0.&#xD;
&#xD;
          5. Patient able to sign informed consent and willing to participate in study primary&#xD;
             objectives&#xD;
&#xD;
          6. At least 1 week from last intrathecal chemotherapy (&gt;2 weeks if liposomal cytarabine).&#xD;
             Patients are allowed to have received prior chemotherapy for their tumor. No limit on&#xD;
             prior chemotherapies will be made. Patients who have been treated with tyrosine kinase&#xD;
             inhibitors are permitted. Prior anti-VEGF targeted therapy is not permitted, unless&#xD;
             patient has been off anti-VEGF therapy for 6 months and did not develop NM while on&#xD;
             anti-VEGF therapy&#xD;
&#xD;
          7. Karnofsky performance status (KPS) &gt;/= 50%&#xD;
&#xD;
          8. Pre-treatment CSF Indium 111 CSF flow study without evidence of obstruction.&#xD;
&#xD;
          9. Patients on full-dose anticoagulants (e.g., warfarin) with PT international normalized&#xD;
             ratio (INR) &gt;1.5 are eligible provided that: 1. Patients are receiving anticoagulation&#xD;
             (warfarin or low molecular weight heparins (LMWH)) only if the patients can be off of&#xD;
             warfarin for 4-5 days prior to the LP and placed on LMWH in that interim, and if the&#xD;
             'treatment dose' of LMWH can be safely held for 24 hours before and after the LP.&#xD;
&#xD;
         10. ( 9. continued) INR must be &lt;1.2 prior to LP in this circumstance. If patients are&#xD;
             receiving thromboprophylaxis dose of LMWH, the patients can be enrolled, but the&#xD;
             thromboprophylaxis LMWH must be able to be safely held for 12 hours prior to the LP.&#xD;
             2. The patient has no active bleeding or pathological condition that carries a high&#xD;
             risk of bleeding 3. There is no evidence of serious or non-healing wound, ulcer or&#xD;
             bone fracture&#xD;
&#xD;
         11. Ventricular reservoir NOT mandatory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of active CNS hemorrhage in the brain or tumor lesions&#xD;
&#xD;
          2. Besides NM, other known CNS disease, except for treated brain metastases(Patients must&#xD;
             be at least 1 month out from brain irradiation and have no evidence of progression or&#xD;
             hemorrhage at that time, as ascertained by clinical examination and brain imaging (MRI&#xD;
             or CT) during the screening period). Anticonvulsants (stable dose) are allowed.&#xD;
             Treatment for brain metastases may include whole brain radiotherapy, radiosurgery or a&#xD;
             combination as deemed appropriate by the treating physician.&#xD;
&#xD;
          3. (2. continued) With respect to irradiation for other purpose (for NM or bone&#xD;
             metastases, etc) patients need only 1 week out from the completion of irradiation.&#xD;
             Patients with CNS metastases treated by neurosurgical resection or brain biopsy&#xD;
             performed within 3 months prior to Day 1 will be excluded.&#xD;
&#xD;
          4. Patients with clinically significant cardiovascular disease are excluded 1)&#xD;
             Inadequately controlled HTN (SBP &gt; 140 mmHg and/or diastolic blood pressure (DBP) &gt; 90&#xD;
             mmHg despite antihypertensive medication). 2) Prior history of hypertensive crisis or&#xD;
             hypertensive encephalopathy. 3) New York Heart Association (NYHA) Grade II or greater&#xD;
             congestive heart failure.&#xD;
&#xD;
          5. ( 4. Continued) 4) History of myocardial infarction or unstable angina within 6 months&#xD;
             prior to Day 1. 5) History of stroke or transient ischemic attack within 6 months&#xD;
             prior to Day 1. 6) Significant vascular disease (e.g., aortic aneurysm, requiring&#xD;
             surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day&#xD;
             1. 7) Clinically significant peripheral vascular disease. 8) Serious and inadequately&#xD;
             controlled cardiac arrhythmia&#xD;
&#xD;
          6. History of hemoptysis (&gt;/= 1/2 teaspoon of bright red blood per episode) within 1&#xD;
             month prior to Day 1&#xD;
&#xD;
          7. Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 1 or anticipation of need for major surgical procedure during the course&#xD;
             of the study&#xD;
&#xD;
          9. Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to Day 1. Ventricular reservoir must have been&#xD;
             placed more than 28 days prior to Day 1.&#xD;
&#xD;
         10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to&#xD;
             Day 1&#xD;
&#xD;
         11. Serious, non-healing wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
         12. Proteinuria as demonstrated by UPC ratio &gt;/=1.0 at screening or by urine dipstick &gt;/=&#xD;
             2+. (Patients discovered to have &gt;/= 2+ proteinuria on urinalysis at baseline should&#xD;
             undergo a 24 hour urine collection and must demonstrate &lt;/= 1g of protein in 24 hours&#xD;
             to be eligible).&#xD;
&#xD;
         13. Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
         14. Intrathoracic or extrathoracic lung carcinoma of squamous cell histology. Mixed tumors&#xD;
             will be categorized by the predominant cell type unless small cell elements are&#xD;
             present, in which case the patient is ineligible; sputum cytology alone is acceptable.&#xD;
&#xD;
         15. (14. continued) Patients with extrathoracic-only squamous cell NSCLC are eligible.&#xD;
             Patients with only peripheral lung lesions (of any non squamous NSCLC histology,&#xD;
             except small cell histology) will also be eligible (a peripheral lesion is defined as&#xD;
             a lesion in which the epicenter of the tumor is &lt;/= 2 cm from the costal or&#xD;
             diaphragmatic pleura in a three-dimensional orientation based on each lobe of the lung&#xD;
             and is &gt;/= 2 cm from the trachea, main, and lobar bronchi).&#xD;
&#xD;
         16. Pregnant (positive pregnancy test) or nursing women. Angiogenesis is critical to fetal&#xD;
             development and the inhibition of angiogenesis following administration of AVASTIN is&#xD;
             likely to result in adverse effects on pregnancy. There are no adequate and&#xD;
             well-controlled studies in pregnant women. Both fertile men and women must agree to&#xD;
             use adequate contraceptive measures during study therapy and for at least 2 months&#xD;
             after the completion of bevacizumab therapy.&#xD;
&#xD;
         17. General Medical Exclusions 1) Inability to comply with study and/or follow-up&#xD;
             procedures 2) Life expectancy of less than 6 weeks 3) Current, recent (within 4 weeks&#xD;
             of the first infusion of this study), or planned participation in an experimental drug&#xD;
             study other than this Genentech supported study 4) Active malignancy, other than&#xD;
             superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of&#xD;
             the cervix within the last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivo D. Tremont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <results_first_submitted>September 19, 2016</results_first_submitted>
  <results_first_submitted_qc>December 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplastic Meningitis</keyword>
  <keyword>NM</keyword>
  <keyword>Advanced Cancers</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Disorders</keyword>
  <keyword>CNS</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Anti-VEGF monoclonal antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <keyword>Spinal Cord</keyword>
  <keyword>meninges</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: June 15, 2009 to February 28, 2011. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible, Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="24" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells</title>
        <description>CSF response for participants with Neoplastic Meningitis (NM) or leptomeningeal disease (LMD) defined as conversion from positive to negative cytology or cytometry as measured routinely by total clearance of malignant cells from the CSF where assessments performed from 2 weeks up to week 54 of treatment. Clearance of malignant cells determined by standard clinical testing using cytospin analysis in clinical laboratory. Percentage reflects number of participants of total treated with no response, e.g. participants with continued positive CSF cytology or flow cytometry.</description>
        <time_frame>1 year (54 weeks) of treatment</time_frame>
        <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells</title>
          <description>CSF response for participants with Neoplastic Meningitis (NM) or leptomeningeal disease (LMD) defined as conversion from positive to negative cytology or cytometry as measured routinely by total clearance of malignant cells from the CSF where assessments performed from 2 weeks up to week 54 of treatment. Clearance of malignant cells determined by standard clinical testing using cytospin analysis in clinical laboratory. Percentage reflects number of participants of total treated with no response, e.g. participants with continued positive CSF cytology or flow cytometry.</description>
          <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Progression (TTP) and Median Time to Neurological Progression (TTNP)</title>
        <description>Time to Progression defined as time to disease progression measured from date of enrollment, confirmation of disease progression via laboratory testing; Time to neurological progression (TTNP) reflects worsening clinical signs/symptoms or development of new clinical signs/symptoms which investigator feels can be attributed to leptomeningeal disease progression and are severe enough to warrant a change in therapy.</description>
        <time_frame>6 weeks</time_frame>
        <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression (TTP) and Median Time to Neurological Progression (TTNP)</title>
          <description>Time to Progression defined as time to disease progression measured from date of enrollment, confirmation of disease progression via laboratory testing; Time to neurological progression (TTNP) reflects worsening clinical signs/symptoms or development of new clinical signs/symptoms which investigator feels can be attributed to leptomeningeal disease progression and are severe enough to warrant a change in therapy.</description>
          <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TTP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TTNP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Participant Response: Cerebrospinal Fluid (CSF) Examination</title>
        <description>Neoplastic meningitis is considered an unmeasurable metastatic site by Response Evaluation Criteria in Solid Tumors (RECIST), and as such no standardized methodologies are routinely used; therefore response assessed from cerebrospinal fluid (CSF) obtained via lumbar puncture (and from ventricular reservoir if present) and analyzed for malignant cells along with reference recording of magnetic resonance imaging (MRI) of areas of enhancement over time; however, MRI alone in LMD/NM is considered non-evaluable by RECIST criteria. Those participants with only MRI criteria for enrollment, but who later develop CSF positivity after enrollment were declared &quot;progressors&quot; based on the CSF criteria.</description>
        <time_frame>1 year (54 weeks) of treatment</time_frame>
        <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Response: Cerebrospinal Fluid (CSF) Examination</title>
          <description>Neoplastic meningitis is considered an unmeasurable metastatic site by Response Evaluation Criteria in Solid Tumors (RECIST), and as such no standardized methodologies are routinely used; therefore response assessed from cerebrospinal fluid (CSF) obtained via lumbar puncture (and from ventricular reservoir if present) and analyzed for malignant cells along with reference recording of magnetic resonance imaging (MRI) of areas of enhancement over time; however, MRI alone in LMD/NM is considered non-evaluable by RECIST criteria. Those participants with only MRI criteria for enrollment, but who later develop CSF positivity after enrollment were declared &quot;progressors&quot; based on the CSF criteria.</description>
          <population>Of the 20 registered, 5 were screening failures therefore are not included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change/Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data for study collected for up to 54 weeks (about 1 year), up to 30 days after the date of the last drug administration.</time_frame>
      <desc>Of the twenty participants, five were not treated and therefore are not included in the adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab</title>
          <description>Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Gastrointestinal Abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatique</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Unrelated to treatment, Disease progression</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain, Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound Complications/Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphatics (Other)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ocular/Visual (Other)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal (Other)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain (Other)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="34" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory (Other)</sub_title>
                <counts group_id="E1" events="55" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum cacium decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum glucose decrease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal (Other)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neurology (Other)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Laryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pulmonary (Other)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John F de Groot, Professor, Neuro-Oncology</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>(713) 745-3072</phone>
      <email>jdegroot@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

